Current status and research hotspots of cardio-oncology based on bibliometrics

doi:10.19401/j.cnki.1007-3639.2022.10.001

Abstract

Abstract: Background and objective: Cardio-oncology that focuses on the management of cardiovascular toxicity associated with cancer therapy, has grown rapidly worldwide as an emerging interdisciplinary discipline over the past decade. This study aimed to summarize the hot spots and development trends of cardio-oncology to provide a reference for scientific researchers in related fields based on bibliometrics. Methods: CiteSpace was employed to conduct the visualized analysis of annual publications, authors, countries, citations and keywords of the related papers from 2012 to 2022 in the Web of Science Core Collection and China National Knowledge Infrastructure (CNKI). Results: A total of 4 287 English articles and 1 165 Chinese articles were included after screening. At present, the number of foreign literature in the field of cardio-oncology, showed a trend of rapid growth, while our country has "slow development period" and "rapid development period" with 2016 as the boundary. The United States is the country with the largest number of publications in Web of Science, accounting for about 34.21% of the total, followed by China, Italy and other countries. The institutions with the largest number of publications at home and abroad are the University of Texas MD Anderson Cancer Center and the First Affiliated Hospital of Dalian Medical University. Bonnie KY, Ana Barac, Paaladinesh Thavendiranathan are the main contributors abroad, and Xia Yunlong, Zhang Yuhui and Cheng Leilei are the main contributors in China. The most frequently cited literature is the position statement on cancer treatment and cardiovascular toxicity from the European Society of Cardiology. The most frequently used keywords abroad were "heart failure", "breast cancer" and "cardiotoxicity", while the most frequently used keywords in China were "cardiotoxicity", "cardiac tumor" and "doxorubicin". Keywords with the strongest citation bursts at home and abroad in recent three years are "immune checkpoint inhibitors". Conclusion: The research hotspots mainly focus on cardiotoxicity caused by antineoplastic therapy, prevention and treatment, screening and diagnosis of cardiovascular toxicity associated with cancer therapy, etc. Establishing a multidisciplinary diagnosis and treatment model and paying attention to the immune checkpoint inhibitor-related myocarditis and whole process management of cardio-oncology are the directions of future development.

Key words: Cardio-oncology, Cardiotoxicity, Bibliometrics, CiteSpace

CLC Number:

R737

LI Mengjuan, LIU Ying, ZHANG Yanli, LIU Mengyao, XUE Yanan, SU Liping, ZHANG Xiujie, SHI Tieying, FANG Fengqi, LIU Jiwei, XIA Yunlong. Current status and research hotspots of cardio-oncology based on bibliometrics[J]. China Oncology, 2022, 32(10): 925-935.

Figures/Tables 12

Fig. 1

Tab.1

Tab. 2

Tab. 3

Tab. 4

Fig. 2

Fig. 3

Tab. 5

Fig. 4

Fig. 5

Tab. 6

Tab. 7

References 28

[1]	夏云龙, 张运. 萌芽中的肿瘤心脏病学: 机遇与挑战[J]. 中华心血管病杂志, 2017(3): 182-185.
	XIA Y L, ZHANG Y. Oncocardiology in the bud: opportunities and challenges[J]. Chin J Cardiol, 2017(3): 182-185.
[2]	DE BOER R A, MEIJERS W C, VAN DER MEER P, et al. Cancer and heart disease: associations and relations[J]. Eur J Heart Fail, 2019, 21(12): 1515-1525. doi: 10.1002/ejhf.1539 pmid: 31321851
[3]	陈悦, 陈超美, 刘则渊, 等. CiteSpace知识图谱的方法论功能[J]. 科学学研究, 2015, 33(2): 242-253.
	CHEN Y, CHEN C M, LIU Z Y, et al. The methodology function of CiteSpace mapping knowledge domains[J]. Stud Sci Sci, 2015, 33(2): 242-253.
[4]	刘斌亮, 王延风, 马飞. 从肿瘤学出发, 浅谈肿瘤心脏病学的发展、现状与挑战[J]. 中国心血管杂志, 2018, 23(5): 357-359.
	LIU B L, WANG Y F, MA F. Starting from the oncology, analyze the development, situation and challenges of Cardio-Oncology[J]. Chin J Cardiovasc Med, 2018, 23(5): 357-359.
[5]	ZHANG Y, LIU Y, XIA Y. Dedicated to cardio-oncology[J]. Eur Heart J, 2020, 41(8): 907-909. doi: 10.1093/eurheartj/ehaa064 pmid: 32080730
[6]	KY B. JACC: CardioOncology: poised to serve a maturing, collaborative field[J]. JACC CardioOncol, 2019, 1(1): 131-132. doi: 10.1016/j.jaccao.2019.06.001
[7]	LIU Y, ZHANG Y L, LIU J W, et al. Emergence, development, and future of cardio-oncology in China[J]. Chin Med J (Engl), 2018, 131(21): 2640-2644.
[8]	ZHANG Y H, ZHANG Z R, LIU Y, et al. Cardio-oncology in China: we are on the go![J]. JACC CardioOncol, 2020, 2(1): 139-143. doi: 10.1016/j.jaccao.2020.02.007
[9]	ZAMORANO J L, LANCELLOTTI P, RODRIGUEZ MUÑOZ D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2016, 37(36): 2768-2801. doi: 10.1093/eurheartj/ehw211
[10]	ARMENIAN S H, LACCHETTI C, BARAC A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol, 2017, 35(8): 893-911. doi: 10.1200/JCO.2016.70.5400 pmid: 27918725
[11]	PLANA J C, GALDERISI M, BARAC A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging[J]. J Am Soc Echocardiogr, 2014, 27(9): 911-939. doi: 10.1016/j.echo.2014.07.012
[12]	CARDINALE D, COLOMBO A, BACCHIANI G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy[J]. Circulation, 2015, 131(22): 1981-1988. doi: 10.1161/CIRCULATIONAHA.114.013777 pmid: 25948538
[13]	JOHNSON D B, BALKO J M, COMPTON M L, et al. Fulminant myocarditis with combination immune checkpoint blockade[J]. N Engl J Med, 2016, 375(18): 1749-1755. doi: 10.1056/NEJMoa1609214
[14]	GULATI G, HECK S L, REE A H, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol[J]. Eur Heart J, 2016, 37(21): 1671-1680. doi: 10.1093/eurheartj/ehw022 pmid: 26903532
[15]	THAVENDIRANATHAN P, POULIN F, LIM K D, et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review[J]. J Am Coll Cardiol, 2014, 63(25): 2751-2768. doi: 10.1016/j.jacc.2014.01.073
[16]	ZHANG S, LIU X B, BAWA-KHALFE T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity[J]. Nat Med, 2012, 18(11): 1639-1642. doi: 10.1038/nm.2919 pmid: 23104132
[17]	SAWAYA H, SEBAG I A, PLANA J C, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab[J]. Circ Cardiovasc Imaging, 2012, 5(5): 596-603. doi: 10.1161/CIRCIMAGING.112.973321 pmid: 22744937
[18]	CURIGLIANO G, LENIHAN D, FRADLEY M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations[J]. Ann Oncol, 2020, 31(2): 171-190. doi: S0923-7534(19)36080-6 pmid: 31959335
[19]	LYON A R, YOUSAF N, BATTISTI N M L, et al. Immune checkpoint inhibitors and cardiovascular toxicity[J]. Lancet Oncol, 2018, 19(9): e447-e458. doi: 10.1016/S1470-2045(18)30457-1
[20]	中国抗癌协会整合肿瘤心脏病学分会中华医学会心血管病学分会肿瘤心脏病学学组中国医师协会心血管内科医师分会肿瘤心脏病学专业委员会, 等. 免疫检查点抑制剂相关心肌炎监测与管理中国专家共识(2020版)[J]. 中国肿瘤临床, 2020, 47(20): 1027-1038.
	Society of Integrative Cardio-Oncology China Anti-Cancer Association, the Cardio-Oncology Group of the Chinese Society of Cardiovascular Diseases of Chinese Medical Association, Chinese College of Cardiovascular Physicians Specialized Committee on Cardio-Oncology Chinese Medical Doctor Association, et al. Chinese expert consensus on the surveillance and management of immune checkpoint inhibitor-related myocarditis (2020 version)[J]. Chin J Clin Oncol, 2020, 47(20): 1027-1038.
[21]	马军, 秦叔逵, 沈志祥. 蒽环类药物心脏毒性防治指南(2013年版)[J]. 临床肿瘤学杂志, 2013, 18(10): 925-934.
	MA J, QIN S K, SHEN Z X. Guidelines for the prevention and treatment of cardiotoxicity of anthracycline drugs (2013 edition)[J]. Chin Clin Oncol, 2013, 18(10): 925-934.
[22]	李艳阳, 王云姣, 韩德军, 等. 基于数据挖掘的中医药治疗抗肿瘤药物心脏毒性用药规律研究[J]. 中国中医基础医学杂志, 2022, 28(1): 138-141.
	LI Y Y, WANG Y J, HAN D J, et al. Research on medication rule of cardiotoxicity with traditional Chinese medicine based on data mining[J]. J Basic Chin Med, 2022, 28(1): 138-141.
[23]	薛静娴, 卞卫和, 姚昶. 中药汤剂治疗乳腺癌患者蒽环类药物化疗心脏毒性的meta分析[J]. 世界科学技术-中医药现代化, 2018, 20(6): 922-928.
	XUE J X, BIAN W H, YAO C. Meta-analysis of curative effects of traditional Chinese herbal decoction on breast carcinoma patients in doxorubicin-induced cardiotoxicity[J]. Mod Tradit Chin Med Mater Med World Sci Technol, 2018, 20(6): 922-928.
[24]	BROWN S A. Preventive cardio-oncology: the time has come[J]. Front Cardiovasc Med, 2019, 6: 187. doi: 10.3389/fcvm.2019.00187
[25]	LYON A R, DENT S, STANWAY S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society[J]. Eur J Heart Fail, 2020, 22(11): 1945-1960. doi: 10.1002/ejhf.1920
[26]	LYON A R, LÓPEZ-FERNÁNDEZ T, COUCH L S, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2022.
[27]	PLANA J C, THAVENDIRANATHAN P, BUCCIARELLI-DUCCI C, et al. Multi-modality imaging in the assessment of cardiovascular toxicity in the cancer patient[J]. JACC Cardiovasc Imaging, 2018, 11(8): 1173-1186. doi: 10.1016/j.jcmg.2018.06.003
[28]	ARMSTRONG G T, KAWASHIMA T, LEISENRING W, et al. Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study[J]. J Clin Oncol, 2014, 32(12): 1218-1227. doi: 10.1200/JCO.2013.51.1055 pmid: 24638000

Country	Centrality	Article n
USA	0.31	1 467
China	0.04	651
Italy	0.05	466
Canada	0.11	279
UK	0.13	238
Germany	0.03	203
Japan	0.01	152
Netherlands	0.04	152
Australia	0.11	136
France	0.16	135

No.	WOS		CNKI
No.	Institution	Article n	Institution	Article n
1	The University of Texas MD Anderson Cancer Center	119	Department of Cardiology, First Affiliated Hospital of Dalian Medical University	26
2	University of Pennsylvania	102	Department of Oncology, First Affiliated Hospital of Dalian Medical University	16
3	Mayo Clinic	97	Department of Ultrasound, The First Affiliated Hospital of Anhui Medical University	12
4	Memorial Sloan-Kettering Cancer Center	85	Heart Failure Center, National Center for Cardiovascular Diseases and Fuwai Hospital, CAMS and PUMC	11
5	University of Toronto	81	Shanghai Institute of Cardiovascular Diseases	9
6	Harvard Medical School	79	Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute	8
7	University of Naples Federico Ⅱ	64	Department of Intracardiac, Harbin Medical University Cancer Hospital	8
8	Vanderbilt University	60	Department of Radiotherapy, the Fourth Hospital of Hebei Medical University	8
9	Duke University	57	Tianjin University of Traditional Chinese Medicine	8
10	Massachusetts General Hospital	52	Department of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine	4

No.	WOS		CNKI
No.	Co-occurrence	Keyword	Co-occurrence	Keyword
1	1 043	Heart failure	230	Cardiotoxicity
2	888	Breast cancer	88	Cardiac tumor
3	746	Cardiotoxicity	82	Breast cancer
4	561	Chemotherapy	57	Adriamycin
5	555	Therapy	42	Chemotherapy
6	454	Oxidative stress	38	Tumour
7	390	Doxorubicin	35	Ventricular function
8	337	Risk	31	Doxorubicin
9	335	Cancer	30	Heart failure
10	290	American Society	30	Anthracycline
11	283	Cardiovascular disease	27	Hypertension
12	279	Cardiac dysfunction	25	Adverse reaction
13	273	Congestive heart failure	24	Myocarditis
14	264	Mechanism	22	Cardiac injury
15	243	Echocardiography	20	Lymphoma
16	209	Apoptosis	19	Malignant tumor
17	206	Childhood cancer	19	Radiation therapy
18	200	Management	17	Ultrasonography
19	200	Cardiomyopathy	16	Thoracic tumor
20	192	Prevention	16	Dexrazoxane

Keyword	Strength	Begin	End
Daunorubicin	5.12	2012	2015
Radiation therapy	3.56	2012	2016
Dexrazoxane	3.28	2012	2017
Children	2.49	2012	2014
Epirubicin	2.48	2013	2014
Thoracic tumor	5.38	2014	2016
Cardiogram	2.90	2018	2020
Chemotherapy	2.63	2018	2019
Myocarditis	5.29	2019	2022
Lung cancer	4.34	2019	2020